Disease management
Also, VUNO has obtained regulatory clearance in South Korea for its AI-based screening solution for kidney failure.
Trained on two million skin images, it can perform a range of clinical tasks unlike current models.
Personify’s Transform Weight Management program will provide LucyRx members with personalized, coach-led guidance, incentives and assets to help manage their weight and medication.
The partners will develop and clinically validate an AI tool that integrates into EHRs to accelerate the diagnosis of hypophosphatasia, a rare genetic bone disorder.
The company will grow its clinical team and expand its offerings across GI partner clinics representing 700 physicians, after an 800% rise in patient volume.
The collaboration addresses delays in diagnosis and treatment by leveraging AI to help ensure patients with prostate and breast cancer are identified and treated more promptly.
The company will use the funds to support a 510(k) submission to the FDA for its Flexi-Port SLF-TANL for oncology patients.
Also, fellow Korean medical AI companies have obtained regulatory approvals across global markets.
The company plans to offer an aggregate of 7.9 million shares of its common stock with an initial public offering price between $18 and $20 per share.
The model could be deployed as a decision support tool in emergency departments.